[
  {
    "ts": null,
    "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
    "summary": "Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%.",
    "url": "https://finnhub.io/api/news?id=cf07560a810bd6c414c5a299cfb25bc406cf9793ebdb1f08dfc23a68e5bbc3d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759419420,
      "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
      "id": 136960024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%.",
      "url": "https://finnhub.io/api/news?id=cf07560a810bd6c414c5a299cfb25bc406cf9793ebdb1f08dfc23a68e5bbc3d7"
    }
  },
  {
    "ts": null,
    "headline": "Can Novo Nordisk's Restructuring Program Drive its Return to Growth?",
    "summary": "NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.",
    "url": "https://finnhub.io/api/news?id=5ecdbb6bb9aa76efe900e8bfd0ab66674ce9010ba35dd8cfa6d4230a8d35473b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759418100,
      "headline": "Can Novo Nordisk's Restructuring Program Drive its Return to Growth?",
      "id": 136960112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.",
      "url": "https://finnhub.io/api/news?id=5ecdbb6bb9aa76efe900e8bfd0ab66674ce9010ba35dd8cfa6d4230a8d35473b"
    }
  },
  {
    "ts": null,
    "headline": "Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?",
    "summary": "Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.",
    "url": "https://finnhub.io/api/news?id=8d687c97057e476f96c06879559a7b7f894130bb1ceea45fbd112b66696ef077",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759415520,
      "headline": "Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?",
      "id": 136960113,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.",
      "url": "https://finnhub.io/api/news?id=8d687c97057e476f96c06879559a7b7f894130bb1ceea45fbd112b66696ef077"
    }
  },
  {
    "ts": null,
    "headline": "LEXX: Biodistribution Study Results",
    "summary": "By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this",
    "url": "https://finnhub.io/api/news?id=f1eefdbee0d64aa85b27048ed6b95a9f1073358b9f2038592146ef2390d7899a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759413840,
      "headline": "LEXX: Biodistribution Study Results",
      "id": 136959917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this",
      "url": "https://finnhub.io/api/news?id=f1eefdbee0d64aa85b27048ed6b95a9f1073358b9f2038592146ef2390d7899a"
    }
  },
  {
    "ts": null,
    "headline": "Merck Manuals Shares What Patients Need to Know About COPD",
    "summary": "Chronic obstructive pulmonary disease (COPD) is a leading cause of death in many smokers and former smokers.",
    "url": "https://finnhub.io/api/news?id=1215f11cd3f154c8b85ee5d28bf9a488cf1877e7652cacc4dc870f4232e2309f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759412700,
      "headline": "Merck Manuals Shares What Patients Need to Know About COPD",
      "id": 136960115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Chronic obstructive pulmonary disease (COPD) is a leading cause of death in many smokers and former smokers.",
      "url": "https://finnhub.io/api/news?id=1215f11cd3f154c8b85ee5d28bf9a488cf1877e7652cacc4dc870f4232e2309f"
    }
  },
  {
    "ts": null,
    "headline": "Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?",
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "url": "https://finnhub.io/api/news?id=107f41fb1a4b54d4d73bb1d9c3c74f876e3701dae000e81a782072aebc239455",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759411803,
      "headline": "Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?",
      "id": 136960116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
      "url": "https://finnhub.io/api/news?id=107f41fb1a4b54d4d73bb1d9c3c74f876e3701dae000e81a782072aebc239455"
    }
  },
  {
    "ts": null,
    "headline": "Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?",
    "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=d241b7cb8e97014b05de946c4b2d5701a9662c15e78552e0783ca8d8ef5fd8d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759410005,
      "headline": "Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?",
      "id": 136960117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=d241b7cb8e97014b05de946c4b2d5701a9662c15e78552e0783ca8d8ef5fd8d5"
    }
  },
  {
    "ts": null,
    "headline": "HEALTH CANADA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-release Injectable Suspension) from Merck Animal Health",
    "summary": "Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), announced Health Canada's approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly injectable product.",
    "url": "https://finnhub.io/api/news?id=a70848d7c014088c1d44eb7ec664dc51eb97beff437861bd20a85d207589e16e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759406400,
      "headline": "HEALTH CANADA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-release Injectable Suspension) from Merck Animal Health",
      "id": 136955395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), announced Health Canada's approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly injectable product.",
      "url": "https://finnhub.io/api/news?id=a70848d7c014088c1d44eb7ec664dc51eb97beff437861bd20a85d207589e16e"
    }
  },
  {
    "ts": null,
    "headline": "Dow falls nearly 150 points on losses for Merck, Walt Disney stocks",
    "summary": "Dow falls nearly 150 points on losses for Merck, Walt Disney stocks",
    "url": "https://finnhub.io/api/news?id=30ecd83640052c11d1c0d759ff392595bedec13e623a924ef8451ce3955019c1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759403640,
      "headline": "Dow falls nearly 150 points on losses for Merck, Walt Disney stocks",
      "id": 136995135,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow falls nearly 150 points on losses for Merck, Walt Disney stocks",
      "url": "https://finnhub.io/api/news?id=30ecd83640052c11d1c0d759ff392595bedec13e623a924ef8451ce3955019c1"
    }
  },
  {
    "ts": null,
    "headline": "Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?",
    "summary": "This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.",
    "url": "https://finnhub.io/api/news?id=9152f3f3905891e22384792a689f2d1a1f3badce66d86d1728b4b6355bf69aa4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759390112,
      "headline": "Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?",
      "id": 136955396,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.",
      "url": "https://finnhub.io/api/news?id=9152f3f3905891e22384792a689f2d1a1f3badce66d86d1728b4b6355bf69aa4"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co (MRK) Announced Positive Results From Phase 3 HYPERION Trial of WINREVAIR",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 30, Merck & Co., Inc. (NYSE:MRK) announced positive results from its Phase 3 HYPERION trial of WINREVAIR in adults recently diagnosed with pulmonary arterial hypertension. The trial included patients classified as functional class 2 or […]",
    "url": "https://finnhub.io/api/news?id=4e3a065e414ba3338a7a7698a01000de536ddcabdfd41aae558b45f9a37588b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759388138,
      "headline": "Merck & Co (MRK) Announced Positive Results From Phase 3 HYPERION Trial of WINREVAIR",
      "id": 136955397,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 30, Merck & Co., Inc. (NYSE:MRK) announced positive results from its Phase 3 HYPERION trial of WINREVAIR in adults recently diagnosed with pulmonary arterial hypertension. The trial included patients classified as functional class 2 or […]",
      "url": "https://finnhub.io/api/news?id=4e3a065e414ba3338a7a7698a01000de536ddcabdfd41aae558b45f9a37588b5"
    }
  },
  {
    "ts": null,
    "headline": "Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target",
    "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) and increased its price target from $75 to $90. The firm attributed the higher target to favorable financial forecasts and solid earnings results for the first half of 2025. Benchmark’s […]",
    "url": "https://finnhub.io/api/news?id=0d1ad0ba7f217862a927c86f68bf487d4f4f9a4927a9d932fca8ca2261004f0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759383340,
      "headline": "Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target",
      "id": 136955398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) and increased its price target from $75 to $90. The firm attributed the higher target to favorable financial forecasts and solid earnings results for the first half of 2025. Benchmark’s […]",
      "url": "https://finnhub.io/api/news?id=0d1ad0ba7f217862a927c86f68bf487d4f4f9a4927a9d932fca8ca2261004f0b"
    }
  }
]